This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

The content of this website has been produced in line with the BESPONSA®▼ (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA▼ Prescribing Information for Great Britain click here. BESPONSA▼ Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

Dosing

Enable outpatient treatment with convenient 1 hour infusion1​​​​​​​

BESPONSA is dosed three times per 3- to 4-week cycle, over 1 hour on Days 1, 8, and 15, for 1–6 cycles1

Cycle numbers

  • If the patient is proceeding to HSCT, 2 cycles are recommended. A 3rd cycle can be considered if CR/CRi and MRD negativity is not achieved
  • If NOT proceeding to HSCT, a maximum of 6 cycles can be given but BESPONSA should be discontinued after 3 cycles if CR/CRi is not achieved.​​​​​​​

BESPONSA Dosing Regimen

BESPONSA is administered as a 1-hour infusion in 21- or 28-day cycles

*± 2 days (maintain a minimum of 6 days between doses).
†The first cycle of BESPONSA is 21 days, while Cycles 2–6 are each 28 days. Cycle 1 may be extended to 28 days for patients achieving CR/CRi and/or if recovery from toxicity is needed.
‡CR defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukaemic blasts, full recovery of peripheral blood counts (platelets ≥ 100 × 109/L and ANC ≥ 1 × 109/L), and resolution of any EMD; CRi defined as < 5% blasts in the bone marrow and the absence of peripheral blood leukaemic blasts, incomplete recovery of peripheral blood counts (platelets < 100 × 109/L and/or ANC < 1 × 109/L) and resolution of any EMD.
§7-day treatment-free interval starting on day 21.

ANC, absolute neutrophil count; CR, complete remission; CRi, complete remission with incomplete haematological recovery of peripheral blood counts; EMD, extramedullary disease; HSCT, haematopoietic stem cell transplantation; MRD, minimal residual disease.

Explore more

Fast Facts

Download the Fast Facts PDF document to aid your understanding of BESPONSA. SmPC should be consulted for full guidance.

Download here

Pharmacy Guide

Download the guide for Pharmacists for information on dosing, drug interactions, reconstitution, administration, shelf life etc. SmPC should be consulted for full guidance.

Download here

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 of the SmPC for how to report adverse reactions.
References
  1. BESPONSA Summary of Product Characteristics for Great Britain click here. BESPONSA Summary of Product Characteristics for Northern Ireland click here.
PP-INO-GBR-0511. August 2021

Support and resources

Access Support and Resources to read the guidelines or watch videos from leading specialists.

Access here

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No